Stay updated with breaking news from Src kinase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Athenex (ATNX) Sells Revenues from U.S. and European Royalty and Milestone Interests in Klisyri to Sagard Healthcare Partners and Oaktree for $80M streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Over the past ten years, Athenex has established a productive relationship with GenScript and GenScript ProBio as a provider of high-quality reagents and materials to support multiple Research and Development initiatives
52-week low: $3.66 Company Profile Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.